Company intelligence / Profile preview

Setta

Miami Beach, Florida, United Statesunitedmasters.com ↗

Ownership: Private
Development stage: Other

Overview

Pasithea’s lead candidate, PAS004, is a next-generation macrocyclic MEK inhibitor currently in Phase 1/1b clinical trials for neurofibromatosis type 1. Preclinical data show inhibition of ETS2 signaling relevant to inflammatory diseases such as IBD. The company is also exploring applications in solid tumors and immune-mediated diseases

Therapeutic areas: Rare DiseasesNeurologyPsychiatryGastroenterologyOncology
Modalities: Small molecule
Industry: Biotech

Partnerships

No major pharmaceutical or biotech partnerships publicly disclosed as of June 2025.

Beyond the preview

Go deeper on Setta.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Setta.

Explore the full profile